Virta Ventures’ Post

Nucleus Capital, a Germany-based venture capital firm, has closed its EUR 40 million climate deep-tech venture capital fund. The fund focuses on pre-seed and seed-stage companies rethinking food production or industrial production using synthetic biology.   LPs include KfW Capital, European Investment Fund (EIF), Rentenbank, as well as food- and industry-focused family offices.   The Orbit GP team including Philip Mostertz (Lead, Fund Structuring), Michael Schnitker (Fund Structuring), Louise Hertz (SFDR, Regulatory), and Laurin Kühn (Tax) advised Nucleus Capital on all legal, tax, and regulatory aspects during the fund's structuring.   A heartfelt thank you to Dr. Isabella Fandrych, Maximilian Schwarz, and team for the opportunity to support such an innovative and forward-looking project.   #VentureCapital #FundStructuring #SyntheticBiology #TechBiology #AllAboutFunds 

Loved our chat after this interview. What really drives us forward? For Alex Leech, it’s about improving people’s health on a large scale and making a difference through innovation. It’s his passion for helping others that motivates him to get up every morning and work hard to bring life-changing ideas to market. When Alex asked me what drives me, it made me reflect. While I admire the big-picture thinking, my approach is more focused on the small, meaningful steps we can take in the moment. I want to make an impact in the here and now. Whether it’s offering a smile that lifts someone’s mood, holding the door open for someone, or just bringing positive energy into someone’s day. In the end, both of us share the same goal: to help people. Whether it’s through large-scale innovation or small acts of kindness, it’s the desire to make a difference that keeps us going.

Ever interested in Venture Capital world, particularly in Europe? Join Angela McKane, Kustaa Valtonen and me tomorrow (Wed 31 July) online for VC Lab - Meet the Managers (Europe)! I'm looking forward to being part of this event! Registration link in the comments. #vclab #meetthemanagers

Catch up on the latest transactions with our Diagnostics and Tools BlueBook, designed to provide valuable perspectives for industry leaders and private equity professionals. Discover a monthly executive review that captures the essence of valuation trends, M&A developments, and transactions. Key highlights from the October 2024 edition include: 📌Nusano closed a $115MM Series A Financing, led by Verily Life Sciences, Section 32, Wasatch Venture Partners, and American Cancer Society’s BrightEdge 📌Vizgen closed a $150.3MM Series A Financing, led by Arch Venture Partners, Tao Capital Partners, and Northpond Ventures 📌Cytovale closed a $100MM Series A Financing, led by Breakout Ventures, Canada Pension Plan Investment Board, Sands Capital Management, Breakout Ventures, and Global Health Investment Corporation Want to read more? Download using the link below: https://hubs.li/Q02ZCFM90 #InvestmentBanking #MergersAndAcquisitions #LifeSciences #PrivateEquity

We wrote about Atlas Venture's 14th fund a few weeks ago, noting they were eyeing a $450 million pool focused on "discipline." The storied biotech investment firm made it official today (saying they've closed on the raise), and Bruce Booth writes about the "VC Math Problem" in a blog post (linked in comments) #biotechvc #biotechstartups #biotechinvesting

Exciting news! Our portfolio company, Sunairio, has raised $6.4MM in a funding round led by Buoyant Ventures, with support from Constellation Technology Ventures and MassMutual Ventures Climate Tech Fund! Huge congratulations to founder Rob Cirincione. We’re proud to have co-led their first round in 2022 with Thin Line Capital, Intelis Capital and MVP Capital Partners and can’t wait to see what’s next! For the full article, read here:  https://lnkd.in/gK-Nmuar

Thrilled to announce our participation in VC Lab Cohort #17 for emerging venture capitalists! Among the many aspects that drew us to VC Lab was their championing of The Mensarius Oath - a powerful ethical framework for investment professionals. While all eight principles in the oath are fundamental to responsible investing, the fifth resonates with me daily: I promise to treat individuals and opportunities with the respect and the attention deserved in business interactions. Interactions can feel somewhat transactional in the VC world. At Wildwood, we're deeply committed to being fully present and engaged in every founder conversation. While we constantly strive to raise our game, we believe authentic engagement is non-negotiable. Link to the complete Mensarius Oath in the comments below.

Bounce Insights, the Dublin and New York based AI-powered market research platform, has raised $4.5m. The round was led by Act Venture Capital, IRRUS INVESTMENTS, Enterprise Ireland, Digital Irish Venture Fund and industry veteran Ian Kiernan. Read more RTE https://shorturl.at/b8gnz

Join us to explore how BioCatch grew from a $4M startup to a $1.3B acquisition by Permira! If you're a founder or investor, this is worth your time. David Assia, iAngels Chairman, will share insights on: 🔹 The early investment decision 🔹 Navigating challenges, including the loss of its CEO 🔹 Key strategies that led to BioCatch’s growth Register here: https://lnkd.in/e_rgq3Y2

Join our webinar to explore BioCatch’s journey from a $4M startup to a $1.3B acquisition by Permira. iAngels Chairman David Assia will share insights on: 🔹 The early investment decision 🔹 Navigating challenges, including the loss of its CEO 🔹 Key strategies that led to BioCatch’s growth If you're a founder or investor, this is worth your time. Seats are limited! Link in the first comment👇